Table 6.
Clinical trials of innate checkpoint inhibitors in lymphoma.
| Trial ID | Authors | Year | Intervention(s) | Target(s) | Phase | Disease(s) | N | CR | OR | PFS |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT02953509 | Advani et al. | 2018 | Hu5F9-G4 | CD47 | Ib | DLBCL FL |
15 7 |
33% 43% |
40% 71% |
91% at 6.2 months 91% at 8.1 months |
| NCT02216409 | Sikic et al. | 2019 | Hu5F9-G4 | CD47 | I | DLBCL | 2 | 0% | 50% | N.A. |
| NCT02367196 | Abrisqueta et al. | 2019 | CC-90002 | CD47 | I | B-NHL | 24 | 4% | 13% | N.A. |
| NCT02663518 | Johnson et al. | 2019 | TTI-621 | CD47 | Ia | CTCL with SS | 5 | 0% | 80% | N.A. |
| NCT03530683 | Patel et al. | 2020 | TTI-622 | CD47 | I | cHL B-NHL T-NHL |
5 16 4 |
0% 6% 0% |
0% 19% 50% |
N.A. |
| NCT02663518 | Ansell et al. | 2021 | TTI-621 TTI-621 + Rituximab TTI-621 + Nivolumab |
CD47 | I | B-NHL (monotherapy) B-NHL (w/Rituximab) cHL (monotherapy) cHL (w/Nivolumab) T-NHL CLL |
21 35 20 4 40 3 |
5% 9% 0% 25% 3% 0% |
10% 23% 5% 50% 20% 0% |
N.A |
| EUDRACT 2009-011526-33 | Vey et al. | 2018 | Lirilumab | KIR | I | CLL other B-NHL |
6 11 |
0% | 0% | median 19.6 months median not reached |
| NCT01592370 | Armand et al. | 2020 | Lirilumab + Nivolumab | KIR | Ib | cHL B-NHL T-NHL |
21 32 9 |
24% 3% 0% |
76% 13% 22% |
62% at 12 months median 1 months median 6 months |
All disease groups are relapsed/refractory unless otherwise specified. Abbreviations: N, number of patients; CR, complete response, OR, overall response; PFS, progression free survival; N.A., not assessed.